Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 7:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 5-Cog Clear all
Not listed Phase 1Phase 2 Interventional

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

NCT03825367
View directory record Official record
Conditions
AML, Childhood
Interventions
Nivolumab, 5-azacytidine
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 30 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional Results available

Caregiver Outcomes of Alzheimer's Disease Screening

NCT03300180
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Collaborative Dementia Care Program, Screening Only
Behavioral · Other
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 7:45 PM EDT
Terminated Phase 2 Interventional Results available

Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance

NCT03980730
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Azeliragon, Placebo
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlantis, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

NCT00553202
View directory record Official record
Conditions
Leukemia
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, methotrexate, methylprednisolone, tacrolimus, laboratory biomarker analysis, pharmacological study, allogeneic bone marrow transplantation, allogeneic hematopoietic stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 17, 2026, 7:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

NCT03155620
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
168
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional Results available

Cognitive Enhancement in Depression (The COG-D Study)

NCT05400512
View directory record Official record
Conditions
Aging, Depression, Cognitive Symptom
Interventions
Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation)
Behavioral · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Enrolling by invitation Not applicable Interventional

Digital Self-Management and Peer Mentoring Intervention

NCT06763770
View directory record Official record
Conditions
Pediatric Cancer Survivor, Survivorship, Cancer
Interventions
Managing Your Health (MYH), The Usual Care + Educational Control
Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 25 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

NCT03213678
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Malignant Glioma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions
Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Samotolisib, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
125
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo

NCT05107479
View directory record Official record
Conditions
COVID-19 Vaccine Knowledge, COVID-19 Vaccine Beliefs
Interventions
COVID-19 Vaccine IVR Training, Control Condition
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8,959 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Exercise and Pain in CCS

NCT05562193
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Physical activity intervention coupled with standard post-cancer directed treatment care, Standard post-cancer directed treatment care control
Behavioral · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
10 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Physical Activity Post-Cancer for Adolescents and Young Adults

NCT04947709
View directory record Official record
Conditions
Childhood Cancer Survivors
Interventions
Physical Activity
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
10 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 17, 2026, 7:45 PM EDT
Completed No phase listed Observational

Development of Web-Based Mind-Body Trainings for Adults With Subjective Concerns

NCT06410807
View directory record Official record
Conditions
Aging, Focus Groups
Interventions
Focus groups
Other
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Enrollment
23 participants
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Benfotiamine in Alzheimer's Disease: A Pilot Study

NCT02292238
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Benfotiamine
Drug
Lead sponsor
Burke Medical Research Institute
Other
Eligibility
60 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

NCT03526250
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Kidney Wilms Tumor, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
115
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Phase 2 Interventional Results available

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

NCT01217437
View directory record Official record
Conditions
Central Nervous System Neoplasm, Pineoblastoma, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Medulloblastoma, Refractory Peripheral Primitive Neuroectodermal Tumor
Interventions
Bevacizumab, Irinotecan Hydrochloride, Temozolomide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 103 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 17, 2026, 7:45 PM EDT
Terminated Phase 3 Interventional Results available

2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)

NCT02916056
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Azeliragon 5mg
Drug
Lead sponsor
vTv Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
65
States / cities
Phoenix, Arizona • Tucson, Arizona • Bellflower, California + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 17, 2026, 7:45 PM EDT
Not yet recruiting Not applicable Interventional

Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)

NCT07527273
View directory record Official record
Conditions
Aging, Depression, Cognitive Symptoms
Interventions
Depression Cognitive Training, Non-Specific Cognitive Training, tDCS (active stimulation), tDCS (sham stimulation)
Behavioral · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Phase 1 Interventional Results available

Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT02303821
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Carfilzomib, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
Drug
Lead sponsor
Amgen
Industry
Eligibility
1 Month to 21 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
22
States / cities
Oakland, California • Orange, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

5-Cog Battery for Detecting Cognitive Impairment and Dementia

NCT03816644
View directory record Official record
Conditions
Dementia, Cognitive Impairment, Mild Cognitive Impairment, Neurocognitive Disorders
Interventions
5-Cog, Health Literacy & Grip Assessment
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
1,201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 17, 2026, 7:45 PM EDT
Recruiting Not applicable Interventional

5-Cog 2.0: A Pragmatic Clinical Trial

NCT05515224
View directory record Official record
Conditions
Dementia, Cognitive Impairment
Interventions
5-Cog Paradigm (5-Cog battery coupled with clinical decision tool), Enhanced usual care
Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
6,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Bloomington, Indiana • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Family and Adolescent Motivational Incentives for Leveraging Youth

NCT01736995
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Functional Family Therapy, Motivational Enhancement Tx/Cognitive Behavioral Tx, Contingency Management
Behavioral
Lead sponsor
Oregon Research Institute
Other
Eligibility
13 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 17, 2026, 7:45 PM EDT
Active, not recruiting Phase 2 Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661
View directory record Official record
Conditions
Recurrent Medulloblastoma, Recurrent Ependymoma
Interventions
Irinotecan, Temozolomide, Bevacizumab, Omburtamab I-131, Liothyronine, SSKI, Dexamethasone, Antipyretic, Antihistamine, anti-emetics
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Los Angeles, California • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional

The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response

NCT06050395
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Quality fo Life Questionnaire (FHSI), Vioscreen Food Frequency Questionnaire (FFQ), Educational Handouts, NutritionCoaching, Follow-Up Survey, Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire, Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 17, 2026, 7:45 PM EDT
Completed Not applicable Interventional

Concussion Treatment in Older Adults

NCT05849064
View directory record Official record
Conditions
Concussion, Mild
Interventions
Behavioral Control, Targeted Intervention
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 17, 2026, 7:45 PM EDT